Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021

20210407 document AG EN

Published 7 April 2021
Categorized as 2021, Press release

Availability of Transgene’s 2020 Universal Registration Document

20210401 Transgene mise a disposition ddr 2020 EN

Published 1 April 2021
Categorized as 2021, Press release

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

20210310 Transgene TG4001 randomized Phase II EN

Published 10 March 2021
Categorized as 2021, Press release, TG4001, TG4001

Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022

20210310 Transgene Results 2020 EN

Published 10 March 2021
Categorized as 2021, Press release

Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences

20210302 – Transgene Scientific Conferences

Published 2 March 2021
Categorized as 2021, Invir.IO, Myvac, Press release

Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

20210301 – Transgene BT-001 FPI – EN

Published 1 March 2021
Categorized as 2021, BT-001, Invir.IO, Press release

First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

20210121 TG4050 1st patient HNSCC EN

Published 21 January 2021
Categorized as 2021, Myvac, Press release, TG4050

Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors

20210119 – ANSM Approval BT-001 EN

Published 19 January 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

20210114 Transgene – Appointment Gaelle Stadtler_EN

Published 14 January 2021
Categorized as 2021, Press release

Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors

20201221 – CTA Approval BT-001 – EN

Published 21 December 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Posts pagination

Newer posts Page 1 … Page 16 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu